Actionable insights straight to your inbox

Equities logo

Pressure BioSciences (PBIO) to Present at RedChip’s Global Online Growth Conference

Mr. Richard T. Schumacher, President and CEO of PBIO, is scheduled to present at RedChip's Global Online Growth Conference on Wednesday January 25, 2017, at 11:30am EST.

Pressure BioSciences, Inc.
(“PBI” and the “Company”), a leader in the
development and sale of broadly enabling, pressure cycling technology
(“PCT”)-based sample preparation solutions to the worldwide life
sciences industry, today announced that Mr. Richard T. Schumacher, President
and CEO, is scheduled to present at RedChip’s Global Online Growth Conference
on Wednesday January 25, 2017, at 11:30am EST. The presentation can be
viewed at A live Q&A session will
follow the investor presentation.

RedChip’s Global Online Growth Conference brings together
investors and executives of leading microcap companies, representing a broad
spectrum of interests and sectors, including oil & gas, technology, mining,
healthcare, consumer goods, energy, and more. More than 10,000 investors attend
RedChip’s microcap conference series each year.

No registration is required to participate in the conference.
Start times are subject to change.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells
proprietary laboratory instrumentation and associated consumables to the
estimated $6 billion life sciences sample preparation market. Our products are
based on the unique properties of both constant (i.e., static) and alternating
(i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a
patented enabling technology platform that uses alternating cycles of
hydrostatic pressure between ambient and ultra-high levels to safely and
reproducibly control bio-molecular interactions. To date, we have installed
nearly 300 PCT systems in approximately 160 sites worldwide. There are over 100
publications citing the advantages of the PCT platform over competitive
methods, many from key opinion leaders. Our primary development and sales
efforts are in the biomarker discovery, drug discovery and design, and
forensics areas. Customers also use our products in other areas, such as
bio-therapeutics characterization, soil & plant biology, vaccine
development, and counter-bioterror applications.

In the interest of full disclosure, we call the
reader’s attention to the fact that, Inc. is compensated by the
companies profiled in the Spotlight Companies section. The purpose of these
profiles is to provide awareness of these companies to investors in the micro,
small-cap and growth equity community and should not in any way be considered
as a recommendation to buy, sell or hold these securities. is not
a registered broker dealer, investment advisor, financial analyst, investment
banker or other investment professional. We are a publisher of original and
third party news and information. All profiles are based on information that is
available to the public. The information contained herein should not be
considered to be complete and is not guaranteed by to be free from
misstatement or errors. The views expressed are our own and not intended to be
the basis for any investment decision. Readers are reminded to do their own due
diligence when researching any companies mentioned on this website. Always bear
in mind that investing in early-stage companies is risky and you are encouraged
to only invest an amount that you can afford to lose completely without any
change in your lifestyle. Equities has been compensated with cash, common
shares and/or warrants for market awareness services provided.

Amid regulatory scrutiny, high volatility and a steep decline in crypto's credibility, is a Bitcoin boom cycle possible?